NO | פּראָדוקטן | פאַל | שליסל קוואַליטעט גראדן | |||
ריינקייַט | מאַקס. טומע | גאַנץ סאַלוואַנט רעזאַדו | נעץ | |||
1 | FMOC-β-Ala-Ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
2 | Fmoc-d-ala-d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
3 | Fmoc-β-Ala-d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
4 | FMoc-Arg (PBF) -אַרג (פּבף) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
5 | FMOC-β-AlA-arg (pbf) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
6 | FMOC-D-Arg (PBF) -D-arg (pbf) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
7 | FMOC-β-Ala-d-arg (pbf) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
8 | Fmoc-homoarg (פּבף) -האָמאָאַרג (פּבף) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
9 | FMOC-β-Ala-homoarg (pbf) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
10 | FMOC-ASN (TRT) -אַס (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
11 | FMOC-β-Ala-asn (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
12 | FMoc-ASP (OTBU) -אַס (OTBU) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
13 | FMoc-β-AlA-ASP (OTBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
14 | Fmoc-cys (trt) -cys (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
15 | FMOC-β-Ala-cys (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
16 | FMoc-CYS (ACM)-סעקונדעס (ACM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
17 | FMoc-β-Ala-cys (ACM) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
18 | FMOC-GLN (TRT) -GLN (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
19 | FMOC-β-Ala-rgn (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
20 | FMOC-GLU (OTBU) -GU (OTBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
21 | FMoc-β-Ala-Glu (Otbu) -oh.h2o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
22 | FMOC-β-Ala-GLY-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
23 | פמאָק-זיין (טרט) -היס (טרט) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
24 | FMOC-β-Ala-thy (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
25 | FMoc-ile-ile-Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
26 | FMOC-β-Ala-ile-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
27 | FMoc-Leu-Leu-Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
28 | FMOC-β-Ala-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
29 | FMOC-D-LEU-D-LEU-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
30 | FMOC-β-Ala-d-Leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
31 | FMoc-Lys (Boc) -לייס (BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
32 | FMOC-β-Ala-Lys (Boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
33 | FMoc-Lys (Alloc) -לייס (Alloc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
34 | FMOC-β-Ala-Lys (Alloc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
35 | FMOC-MET-MET-טאַקע | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
36 | FMOC-β-Ala-mew-ho | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
37 | FMoc-orr (boc) געשעפט (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
38 | FMOC-β-Ala-rr (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
39 | FMoc-PHE-PHE-טאַקע | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
40 | FMOC-β-Ala-Qhe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
41 | FMOC-D-PHE-D-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
42 | FMOC-β-Ala-d-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
43 | FMoc-Pro-Pro-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
44 | FMOC-β-AlA-Pro-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
45 | Fmoc-ser (tbu) -ser (tbo) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
46 | FMoc-β-Ala-ser (tbo) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
47 | Fmoc-ser (trt) -שר (טרט) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
48 | FMoc-β-Ala-ser (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
49 | Fmoc-th (tbu) -טר (טבו) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
50 | FMoc-β-Ala-th (tbo) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
51 | Fmoc-trp (boc) -טרק (באָק) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
52 | FMOC-β-Ala-trp (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
53 | Fmoc-d-trp (boc)-d-trp (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
54 | FMOC-β-Ala-d-trp (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
55 | FMoc-Tyr (TBU) -טיר (טבו) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
56 | FMoc-β-Ala-טיר (TBU) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
57 | FMoc-D-Tyr (et) -D-טיר (עט)-אָה | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
58 | FMOC-β-Ala-D-טיר (עט)-אָה | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
59 | Fmoc-טיר (מיר) -טיר (מיר) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
60 | FMOC-β-Ala-טיר (מיר) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
61 | FMoc-Val-Val-טאַקע | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
62 | FMOC-β-Ala-val-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
63 | FMOC-D-CIT-D-CIT-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
64 | FMOC-β-Ala-d-sif-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
65 | FMOC-β-AlA-dab-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
66 | Fmoc- (3- (2-נאַפטהיל) -ד-אַלאַ) 2-טאַקע | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
67 | FMOC-β-Ala-3- (2-נאַפטהיל) -ד-אַלאַ-אָה | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
68 | Fmoc- (3- (3-פּירידיניל) -ד-אַלאַ) 2-טאַקע | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
69 | FMoc-β-Ala-3- (3-פּירידיניל) -ד-אַלאַ-אָה | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
70 | Fmoc- (4-טשלאָראָ-ד-פי) 2-טאַקע | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
71 | FMOC-β-AlA-4-Chloro-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
72 | FMoc- (D-4f (TBUCBM)) 2-טאַקע | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
73 | FMOC-β-Ala-d-4ff (TBUCBM) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
74 | FMoc-Aph (L-Hor) -אַפ (L-Hor) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
75 | FMOC-β-Ala-aph (l-gor) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
76 | FMoc-Lys (iPR, BOC) -ליי (IPR, BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
77 | FMoc-β-Ala-Lys (IPR, BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
78 | FMOC-β-Ala-aeea-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
79 | פמאָק-אַיב-אַיב-אָה | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
80 | FMOC-β-AlA-AIB-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
81 | פמאָק-אַרג-אָה | 91000-69-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
82 | H- אַרג (פּבף) -oh | 20015-86-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
83 | FMoc-D- אַרג-טאַקע | 130752-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
84 | הד-אַרג (פּבף) -oh | 200116-81-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
85 | Fmoc-homoarg-no.hcl | 208174-14-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
86 | ה-האָמאָאַרג (פּבף) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
87 | Fmoc-d-homoarg-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
88 | הד-כאָומאָאַרג (פּבף) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
89 | Fmoc-onn-oh | 71989-16-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
90 | H-ASN (TRT) -oh | 132388-58-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
91 | FMoc-ASP-טאַקע | 119062-05-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
92 | H-ASP (OTBU) -OH | 3057-74-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
93 | FMoc-CYS-OH | 135248-89-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
94 | H-CYS (TRT) -oh | 2799/7/7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
95 | H-CYS (ACM) -oh.hcl | 28798-28-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
96 | FMOC-GLN-טאַקע | 71989-20-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
97 | ה-גן (טרט) -oh | 102747-84-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
98 | FMOC-GLU-טאַקע | 121343-82-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
99 | H- Glu (Otbu) -oh.h2o | 2419-56-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
100 | פמאָק-זיין-טאַקע | 116611-64-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
101 | ה-זיין (טרט) -oh | 35146-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
102 | Boc-bish | 17791-52-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
103 | פמאָק-ליס-טאַקע | 105047-45-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
104 | H-Lys (Boc) -oh | 2418-95-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
105 | H-Lys (Alloc) -oh | 6298/3/9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
106 | Fmoc-orr-oh.hcl | 201046-57-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
107 | ה-אָרר (באָק) -oh | 13650-49-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
108 | Fmoc-ser-oh | 73724-45-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
109 | H-Ser (TBU) -oh | 18822-58-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
110 | H-Ser (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
111 | Fmoc-tr-oh.h2o | 73731-37-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
112 | ה-טה (טבו) -oh | 4378-13-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
113 | FMOC-TRP-טאַקע | 35737-15-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
נאך 114 | H-TRP (BOC) -oh | 146645-63-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
115 | FMOC-D-TRP-טאַקע | 86123-11-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
116 | הד-טרפּ (באָק) -oh | 201290-11-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
117 | FMoc-Tyr-oh | 92954-90-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
118 | ה-טיר (טבו) -oh | 18822-59-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
119 | FMoc-D-Tyr-oh | 112883-29-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
120 | הד-טיר (עט)-אָה | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
121 | ה-טיר (מיר) -oh.hcl | 67423-44-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
122 | FMOC-D-4אַף (CBM) -oh | 324017-22-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
123 | הד -4אַף (טבוקבם) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
124 | FMoc-Lys (IPR) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
125 | H-Lys (iPR, BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
פאַרגיטיקונג
Gentolex צושטעלן גרויס קוואַליטעט פּראָדוקטן, אויב קיין פּראָדוקט קוואַליטעט איז אויפגעשטאנען דורך די פארלאנגט צייט ראַם מיט גענוג ווידז, מיר וועלן צושטעלן נייטיק אַנאַליסיס און אפשאצונג צו צינגל די פּראָוסידזשערז פון קאַמפּאַנסיישאַנז.
פּראָדוקציע
די קאַפּאַסאַטיז פון פאַרמאַסוטיקאַל פּראָדוקטן ריטשט די מיינונג, די קאַפּאַסאַטיז פון כעמישער פּראָדוקטן דערגרייכן 100 ons + מיינונג, די קייפּאַבילאַטיז זענען געזונט יקוויפּט צו דינען קלייאַנץ ווערייץ.
פאָרשונג און אַנטוויקלונג
יעדער יאָר, עס איז פּלאַנירן סעטטינגס דורך די ר & די מאַנשאַפֿט צו אַנטוויקלען פאַרשידענע נייַע פּראָדוקטן, ווען טאַרגאַץ שטעלן, יעדער מיטגליד אין דער מאַנשאַפֿט וועט האָבן צו פאָרזעצן מיט KPI פֿאַראַנטוואָרטלעכקייט און מיט ינסענטיוו פּאָליטיק.